Reading EMBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EMBC free→Reading EMBC? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track EMBC free→NASDAQHealth CareMedical Instruments & SuppliesSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady. Earnings quality is neutral, and risk is elevated, while the sector backdrop is a headwind. Peer multiples imply a price about 64% above where it trades (it looks cheap on this basis); the read is cheap, quality intact. Key factors to watch include whether EMBC raises guidance next quarter and the performance of sector bellwethers like ISRG, MDLN, and BDX. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $3.13. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $3.13 EMBC trades at 1× p/e, below its 23× p/e peer median. Our $9.07 fair value sits above the price; medium confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 65% below a flat-multiple fair value, below our forecast of about -2%. This describes what's priced in, not a forecast of the move.
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.91x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, real (inflation-adjusted) rates, Fed net liquidity, long-term interest rates.
2 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.82 → $0.27 (-67.6% / 30d). 0 raised, 4 cut, 4 covering analysts.
0 upgrades, 0 downgrades / 30d, 1 maintained. 0% of analysts rate Buy.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$150.
How much price usually moves either way.
On a bad day, this stock has moved -$548.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,053.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: U.S. revenue performance will indicate if competitive pressures are easing or worsening. It is crucial for overall growth.
Confirms:U.S. revenues show a decline of less than 18% year over year in Q3 2026.
Disproves:U.S. revenues decline more than 20% year over year in Q3 2026.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for EMBC yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Completion of Acquisition or Disposition of Assets. On May 15, 2026, Embecta Corp. (“embecta”) completed its previously announced acquisition (the “Transaction”) of all of the issued share capital of Owen Mumford Holdings Limited (“Owen Mumford”), a privately held, UK-based innovator and manufacturer of medical devices and drug-delivery technologies. The Transaction was completed pursuant to an Agreement for the Sale and Purchase of Owen Mumford Holdings Limited (the “Purchase Agreement”), da…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
A side-by-side read on sector standing, valuation, and risk versus Health Care Equipment.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
EMBC Embecta Corp. | Typical Show detailsSector percentile: 54 of 100 | inexpensive | elevated |
ABT Abbott Laboratories | Above typical Show detailsSector percentile: 94 of 100 | fair | moderate |
ISRG Intuitive Surgical | Above typical Show detailsSector percentile: 94 of 100 | expensive | moderate |
SYK Stryker Corporation | Above typical Show detailsSector percentile: 71 of 100 | fair | moderate |
MDT Medtronic | Above typical Show detailsSector percentile: 89 of 100 | fair | moderate |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Finalize the acquisition of Owen Mumford to expand product portfolio and strengthen B2B drug delivery platform.
Conduct a comprehensive review of the cost structure and organizational footprint to identify efficiencies.
Implement a three-year $100 million share repurchase program to enhance shareholder value.
Reduce the quarterly cash dividend from $0.15 to $0.01 per share to increase financial flexibility.
Continue to provide a consistent dividend payout of $0.15 per share.
Why it matters: Keeping the dividend shows a commitment to shareholders. This is important during tough times.
Confirms:Embecta declares a dividend of $0.15 per share in Q3 2026.
Disproves:Embecta cuts the dividend below $0.15 per share in Q3 2026.
Why it matters: Earnings results will provide insight into revenue trends and operational performance. This is crucial for assessing growth.
Confirms one read:Q2 earnings show revenue growth or stabilization in U.S. business.
Confirms the other:Q2 earnings report shows continued revenue decline in U.S. business.
Why it matters: The dividend cut may affect investor sentiment and stock price. This reflects how the market views embecta's financial health.
Confirms:The share price stays the same or goes up after the dividend cut announcement.
Disproves:The share price drops a lot after the dividend cut announcement.
Why it matters: The review shows how embecta will improve efficiency and manage costs. This impacts profits.
Confirms one read:Management shares a plan to cut costs and boost efficiency.
Confirms the other:Management does not provide a clear plan or timeline for cost changes.
Why it matters: Sales from Owen Mumford will show if the acquisition boosts embecta's growth. This is key for long-term value.
Confirms:Owen Mumford's sales are over £50 million in the first year after the acquisition.
Disproves:Owen Mumford's sales fall below £30 million in the first year after acquisition.
Why it matters: These payments depend on the sales of the Aidaptus auto-injector. Strong sales would confirm the acquisition's value.
Confirms:Owen Mumford's Aidaptus net sales are over £50 million in the first three years.
Disproves:Aidaptus net sales fall below £30 million in the same period.
Why it matters: Better operating income shows that costs are managed well. It also means more efficiency.
Confirms:Operating income increases to above $40M in Q3 2026.
Disproves:Operating income remains below $35M in Q3 2026.
Why it matters: Updates on the share buyback program show management's trust in the company's value.
Confirms:Management says they will complete at least $50 million in share buybacks in a year.
Disproves:No major share buybacks are reported in the next year.
Results of Operations and Financial Condition. On May 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended March 31, 2026. The Press Release is furnished as Exhibit 99.1 to this report.
Entry into a Material Definitive Agreement. On March 19, 2026, Embecta Corp. (“embecta”) entered into a definitive Agreement for the Sale and Purchase of Owen Mumford Holdings Limited (the “Purchase Agreement”) with Mark Owen, Adam Mumford (in his individual capacity and in his capacity as trustee of the Mumford Family 2026 Trust), Anne Mumford (in her capacity as trustee of the Mumford Family 2026 Trust), Ellen Owen, Kim Priddis and Nancy Millington (together, the “Sellers”) pursuant to whic…
Results of Operations and Financial Condition. On February 5, 2026, Embecta Corp. issued a press release (the “Press Release”) regarding its results for the quarter ended December 31, 2025. The Press Release is furnished as Exhibit 99.1 to this report.